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Abstract
To analyze the genetic alterations of pheochromocytomas and evaluate the difference among
malignant, extra-adrenal, and benign pheochromocytomas. Forty-three tumor samples were tested
forgeneticchangesusingmultiplexligation-dependentprobeampliﬁcation.Amongthem,39samples
were available for protein expression analysis by immunohistochemistry (IHC). All 43 patients
(24 women and 19 men; mean age 44.6G13.6 years; range 18–75 years; 9 with malignant, 7 extra-
adrenal, and 27 benign) showed multiple copy number losses or gains. The average copy number
change was 13.10 in malignant, 13.93 in benign, and 13.47 in paraganglioma patients. There is no
signiﬁcant differenceamongthe three groupsof pheochromocytomas. However,wediscovered that
inthemalignantpheochromocytomas,6ofthe9patients(67%)showederythroblasticleukemiaviral
oncogenehomolog2(ERBB-2)oncogenegain,whereasonly12ofthe34(35%)identiﬁedchangein
the benign and extra-adrenal pheochromocytomas. Further, IHC conﬁrmed that ERBB-2-positive
stainingwasmorefrequentandstrongerinmalignantpheochromocytomasthaninbenignandextra-
adrenal pheochromocytomas. Our study illustrates the chromosomal changes of the whole genome
ofChinesepheochromocytomapatients.Theresultssuggestthattheremaybecertainprogressionof
genetic events that involveschromosomes1p,3p, 6p, 11q, 12q, 17q, and 19q in the developmentof
pheochromocytomas,andtheactivationofERBB-2locatedonchromosome17qisanimportantand
early event in the malignancy development of these tumor types. The overexpression of ERBB-2
identiﬁed by IHC suggested that this oncogene could be associated with the malignancy of
pheochromocytomas and paragangliomas.
Endocrine-Related Cancer (2008) 15 343–350
Introduction
Pheochromocytomas are rare neoplasms of the chro-
mafﬁn cells that derived from the embryonic neural
crest. They usually occur within the adrenal medulla;
however, extra-adrenal pheochromocytomas may
arise in ganglia of the sympathetic nervous system.
Both the clinical and biochemical features of
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overproduction of catecholamines. In sporadic pheo-
chromocytomas and paragangliomas, w20% of them
are associated with germline mutations that lead to
paraganglioma syndrome (succinate dehydrogenase
subunit B/C/D; SDHB, SDHC, and SDHD), von
Hippel–Lindau syndrome (VHL), and multiple
endocrine neoplasia type II (MEN2) and, to a much
lesser extent, type 1 neuroﬁbromatosis (NF1; Casanova
et al. 1993, Maher & Kaelin 1997, Neumann et al.
2002, Bausch et al. 2006). Studies of genomic
alterations in primary pheochromocytomas using
comparative genomic hybridization (CGH) have
shown the loss of chromosomes 1p, 3p, 3q, 11p, 17p,
and 22q at various frequencies, suggesting the
existence of tumor suppressor gene loci in these
locations (Yokogoshi et al. 1990, Moley et al. 1992,
Shin et al. 1993, Zeiger et al. 1995, Edstrom et al.
2000). Gain of chromosomes 17q and 11q13 was more
frequently identiﬁed in malignant tumors (August et al.
2004, Eisenhofer et al. 2004, Casco ´n et al. 2005).
However, it is difﬁcult to identify which speciﬁc gene
was involved in the pathogenesis of pheochromo-
cytoma by CGH analysis. Until recently, there was lack
of knowledge about the exact genes involved in the
pathogenesis of sporadic pheochromocytoma. To ﬁnd
new candidate genes, we performed multiplex ligation-
dependent probe ampliﬁcation (MLPA) analysis in
pheochromocytomas. MLPA is a new technique used
to measure the copy number of up to 45 nucleic acid
sequences in one single reaction (Schouten et al.2002).
This method relies on sequence-speciﬁc probe hybridi-
zation to genomic DNA followed by multiplex-PCR
ampliﬁcation of the hybridized probe and semi-
quantitative analysis of the resulting PCR products.
This method is easy to perform and could offer
an alternative to CGH studies (Hogervorst et al.
2003, Bremmer et al. 2005, van Dijk et al. 2005,
Postma et al. 2005).
We investigated 43 pheochromocytoma tissue
samples using MLPA analysis and found that
several genes may contribute to the tumorigenesis
of pheochromocytoma or malignancy of the disease.
These results were similar to those detected by CGH
analysis. The most obvious was the gain of erythro-
blastic leukemia viral oncogene homolog 2 (ERBB-2)
oncogene located on chromosome 17q that was
more common in malignant pheochromocytomas.
Moreover, we analyzed the ERBB-2 oncogene products
from pheochromocytomas by immunohistochemistry
(IHC); the results conﬁrmed the previous genetic
analysis.
Materials and methods
Patients and samples
Forty-three patients (24 women and 19 men; mean age
44.6G13.6 years; range 18–75 years) operatively
proven with sporadic pheochromocytomas were
included in this study. The diagnosis of pheochromo-
cytoma was conﬁrmed on the basis of clinical
manifestations including persistent or paroxysmal
hypertension with the classic triad of severe headaches,
palpitations, and diaphoresis, biochemical features
including serum and urinary metanephrine (MN),
nor-MN (NMN), and positive CT or
131I-MIBG scan.
The diagnosis of malignant pheochromocytoma
was based on the presence of distant metastases or
lymph node inﬁltrations, that is, the presence of
chromafﬁn tissue at sites where this tissue is normally
absent (Eisenhofer et al. 1999, Weise et al. 2002,
Mittendorf et al. 2007). Of the 43 patients, 9 had
malignant disease, 7 were paragangliomas of the
abdomen, and the rest of the 27 patients were with
benign pheochromocytomas. All of the patients were
operated in between 2002 and 2006 and clinically
monitored at the Shanghai Clinical Center for
Endocrine and Metabolic Diseases in the Ruijin
Hospital. The study was approved by the Ethics
Committee of the Ruijin Hospital, Shanghai JiaoTong
University School of Medicine.
Tumor tissues were snap-frozen in liquid nitrogen
immediatelyaftersurgery.GenomicDNAwasextracted
from fresh-frozen tumor specimens by standard
procedures using a Qiagen DNA extraction Kit
(Qiagen)accordingtomanufacturer’sguide.Allpheoch-
romocytomas were histologically analyzed before
DNA extraction to ensure preparation of a population
of the tumor cells without cross-contamination with
the normal cells.
Multiplex ligation-dependent probe ampliﬁcation
We performed MLPA analysis using SALSA P005
and P006 Chromosomal Aberration MLPA Kits
(MRC-Holland, Amsterdam, The Netherlands; details
available at http://www.mlpa.com) and following the
manufacturer’s protocol. The P005 and P006 kits
include 76 genes loci, which were selected because of
their reported involvement in cancer and can span all
23 chromosomes including the X and the Y. With the
MLPA, DNA samples were heated at 98 8C for 5 min;
after the addition of the probe mix, samples were
heated for 1 min at 95 8C and then incubated for 16 h at
60 8C; ligation of the annealed oligonucleotide probes
was performed for 15 min at 54 8C with Ligase-65
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using Cy5-labeled primers, dNTPs, and SALSA
polymerase. PCR was performed for 35 cycles of
30 s at 95 8C, 30 s at 60 8C, and 1 min at 72 8C. All the
reactions were carried out in PTC-225 DNA Engine
Tetrad (MJ Research Inc., San Francisco, CA, USA).
PCR products were analyzed using Beckman Coulter
CEQ 8800 sequencer (Beckman Coulter, Fullerton,
CA, USA). Data analysis was performed with fragment
analysis module. Normal control DNA of males and
females was also used in the same reaction.
MLPA data analysis
The Gene Scan data of sizes and peak height of
multiplex PCR products were exported to an Excel ﬁle.
All the expected MLPA products were normalized by
dividing each peak height by the combined peak height
of all peaks in that lane (relative peak height). The
relative copy number for each probe was expressed as a
ratio of the relative peak height for each locus of the
sample to that of the normal sex-matched control. The
reference median peak heights were obtained from
normal tissue samples, each of which was analyzed at
least thrice independently. Male and female samples
were compared with male and female control samples
respectively for quantitation of X- and Y-linked
probes. The ratio !0.7 and O1.35 was considered as
a loss and a gain respectively.
Immunohistochemistry
IHC analysis was carried out to verify the gene changes
detected by MLPA. To minimize sampling variability,
the following steps were taken. All samples (control
and experimental) were 1) run in parallel and each
treated identically, 2) examinedunder identical con-
ditions, and 3) repeated at least twice. Five micrometer
sections were cut and deparafﬁnized. Then the sections
were immersed in sodium citrate buffer adjusted to pH
6.0 and heated in a microwave oven for 5 min at
100 8C, next treated with 0.3% H2O2 for 30 min to
inhibit peroxidases, then blocked with 2% normal
rabbit serum for 30 min. The slides were incubated
overnight in a solution of ERBB-2 monoclonal
antibody (DAKO Rabbit anti-human ERBB-2 onco-
protein) diluted to 1:200 with the same buffer. The
primary antibody binding was demonstrated with
standard avidin–biotin-peroxidase complex technique
(vector pk-7200). The slides were developed using
diaminobenzidine and counterstained with hematoxylin.
Breast carcinoma tissue, known to express the ERBB-2
protein, was used as the positive control. Negative
controls were incubated with no primary antibody. The
results were evaluated quantitatively and divided into
four groups (0, negative; C, !30% positive rate; CC,
30–60%positiverate;andCCC,O60%positiverate).
The data were entered into a ZEISS Axioplan 2
microcomputer, and statistical analysis was carried out
usingKS4003.0statisticalpackage.TheKruskal–Wallis
test was used to evaluate the relationship among the
percentage of ERBB-2 immunoreactivity (all four
groups) in the benign, extra-adrenal, and malignant
pheochromocytomas.
Results
Clinical characteristics
Forty-three patients were pathologically diagnosed
with pheochromocytoma or abdominal paraganglioma.
Themedianageatdiagnosiswas44.6G13.6years(range
18–75years)withamaletofemalesexdistributionof56
and 44%.Tumors in16patientswereontheleftadrenal,
17ontheright,1withbilateraltumor,andanother9were
with paragangliomas. Of the 43 patients, 18 (42%)
showed one of the classical triad, 11 (25%) showed two,
and 7 (16%) showed all the three triads. However, there
were seven patients with no typical symptoms of
pheochromocytoma. Elevated serum MN and/or NMN
were seen in 95% of the patients. Malignant tumor was
seen in 21% of the patients (Table 1). In 34 benign
samples, 12 showed gain of ERBB-2 with the average
tumor size of 77.1 mm, while the rest 22 showed normal
ERBB-2 gene with the average tumor size of 49.1 mm
(TZ2.729; PZ0.01). The clinical characteristics of
those malignant tumors were shown in Table 2.A l l
the analyzed tumor tissues were derived from the
primary lesions.
Table 1 The clinical features of three different types of pheochromocytomas
Malignant Adrenal benign Paraganglioma benign
Number of patients 9 27 7
Sex (M/F) 2/5 13/14 2/5
Age (averageGstd) 41.1G6.4 45.7G15.7 44.8G13.9
Tumor size (mm) 52.6G19.7 66.3G33.1 40.9G15.2
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Genome-wideanalysissuggestedthatall43pheochromo-
cytoma specimens, including both malignant and
benign ones, showed multiple copy number losses or
gains. In themalignant, benign pheochromocytomas, and
inparagangliomas,thetotalnumberofaberrationsineach
tumor ranged from 6 to 29, 3 to 31, and 7 to 21
respectively,andtheaveragecopynumber changeswere
13.10, 13.93, and 13.47 respectively. Hence, there is no
signiﬁcant difference among the three groups (Fig. 1).
Table 2 The clinical characteristics of malignant patients
Case Sex (M/F) Age (years) Operation times MN/NMN (pg/ml) Tumor size (mm) Metastatic location
5 F 43 3 353.4/30.9 48!40!43 LN
48 F 43 2 167.7/1414.9 40!30!30 LN
68 F 40 2 202.5/585.9 60!50!30 Liver
75 M 40 1 62.6/4669.4 60!50!40 Lung
49 F 44 2 47.2/2172.3 30!10!10 Kidney
67 F 52 2 42.5/5371.6 85!60!30 Omentum
25 F 38 2 8861.3/104.6 75!32!30 Brain
6 M 31 2 170.8/3942.2 50!45!40 LN
72 M 39 1 NA 25!10!10 LN
NA, not available; LN, lymph node. Reference range: NM, 14.0–90.0 pg/ml and NMN, 19–121 pg/ml.
Figure 1 The copy number changes of all 43 analyzed tumors in a total of 76 genes spanning almost all chromosome arms that were
included in the P005 and P006 probe mixes. Colors used: green, gain; red, loss; and white, no genetic alteration. ERBB-2 is
emphasized with purple color.
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the deletionorthe duplicationofthechromosome where
the genes are located.Inour study,chromosomes1p,3p,
9p, and 11p showed obvious deletion, while chromo-
somes 6p, 12q, 17q, and 19q showed duplication.
However, there is no signiﬁcant difference between
malignant pheochromocytomas, paragangliomas, or
benign tumors.
The most obvious difference between malignant and
benign tumors is the duplication of ERBB-2 gene locus
on chromosome 17q21. In malignant tumors, gain of
ERBB-2 gene was the most common abnormality,
whichwasdetectedinsixoutofthenine(67%)patients;
while in paragangliomas and benign pheochromo-
cytomas, only 12 out of the 34 (35%) patients showed
gain of ERBB-2 gene.
Immunohistochemistry
To study the expression of ERBB-2 oncogene in
pheochromocytomas, we further analyzed 39 out of
the 43 samples by IHC analysis. Positive ERBB-2
immunoreactivity showed a diffuse intra-cytoplasmic
granular staining. The frequency of cells expressing the
ERBB-2 protein differed among tumors. All the
malignant pheochromocytoma samples showed
positive ERBB-2 immunoreactivity, among them 86%
were CC or CCC. None of the benign tumors
showed CCC, and 52% of the benign tumors showed
negative immunoreactivity. No immunostaining was
observedinthenegativecontrols(Fig.2).TheKruskal–
Wallis test showed signiﬁcantly higher ERBB-2
oncoprotein expression in the malignant pheochromo-
cytomas (PZ0.0065, K–W test; Table 3).
Discussion
The pheochromocytomas are neuronal–endocrine
tumors arising from the paraganglia system found in
the adrenal medulla, whereas those found along the
para-vertebral and para-aortic axis, but outside the
adrenals, are called paragangliomas. The pheochromo-
cytomas can be a part of some of the hereditary
syndromes, including MEN2, VHL, NF1, and para-
ganglioma syndrome. As the genes responsible for
these hereditary cancer syndromes were identiﬁed,
attention has been shifted to the identiﬁcation of
additional genetic alterations in sporadic pheochromo-
cytomas, especially malignant ones (Neumann et al.
1993, Eisenhofer et al. 2004, Brouwers et al. 2005,
Korpershoek et al. 2007). However, somatic genome
alteration researches are very important to understand
the mechanism of pheochromocytomas. Loss of
chromosome 1p recently detected in pheochromo-
cytomas (Dannenberg et al. 2000, Opocher et al. 2003,
August et al. 2004, Aarts et al.2 0 0 6 ) was the
most frequent chromosomal deletions in our study.
Figure 2 Strong positive staining (CCC) of the malignant pheochromocytoma (top left),CC of the paraganglioma (top right),C of
the benign pheochromocytoma (bottom left), and negative control (bottom right). Magniﬁcation, !40.
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cytomas with similar frequency; therefore, this may be
indicativeofearlyeventsinthetumorigenesisofsporadic
pheochromocytoma. However, these lesions probably
are of less importance in view of the progression to
malignancy. Our study, revealed the frequent gain of
chromosome 17q in malignant tumors, which indicated
thatthisregionmaybeassociatedwiththemalignancyof
the disorders. These results were similar to that detected
by CGH (Brinkschmidt et al.2 0 0 1 , August et al.2 0 0 4 ).
The design of the MLPA analysis takes advantage of
changes not only in chromosome but also in the genes
themselves to demonstrate the relevantgenetic changes
in tumors. In the present study, ERBB-2 oncogene
duplication was observed most frequently in malignant
tumors. ERBB-2 oncogene, originally called NEU
(neuron/glioblastoma derived oncogene homolog),
was derived from the rat neuro/glioblastoma cell
lines. It encodes a tumor antigen, p185, which is
related to the epidermal growth factor receptor. Further
studies proved that ERBB-2 gene product is a 185 kDa
glycoprotein with tyrosine kinase activity (Akiyama
et al. 1986). Overexpression of the ERBB-2, a breast
cancer marker, is associated with rapid tumor growth,
increased risk of recurrence after surgery, poor
response to conventional chemotherapy, and shortened
survival, and this ERBB-2 overexpression has also
been implicated in the neoplastic transformation of
prostate cancer (Ross & Fletcher 1998, Yu et al. 1998).
Trastuzumab (Herceptin) is a human monoclonal
antibody that appears to block the growth signals
transmitted by ERBB-2 to the nucleus and enhances
the response to chemotherapeutic agents (Pietras et al.
1998, Slamon et al. 2001). Antibody against ERBB-2
has been FDA approved for clinical treatment of cancer
under the brand name Herceptin. Some recent clinical
trials have found trastuzumab reduces the risk of
relapse in breast cancer patients by 50% when given in
the adjuvant setting (i.e., after breast cancer surgery,
before the cancer has spread any further) for 1 year
(Piccart-Gebhart et al. 2005, Romond et al. 2005).
In our study, further IHC analysis conﬁrmed that there
was signiﬁcant difference in malignant and benign
pheochromocytomas, which indicated that ERBB-2
oncogene may be an important gene in the malignant
development of pheochromocytomas. The effects of
ERBB-2 in pheochromocytomas pathogenesis may be
similar to that in breast and prostate cancers.
As pheochromocytoma is a rare endocrine tumor,
consequently the specimens included in our study were
limited. With the increase of the tumor samples, the
difference between the malignant and benign tumors
may be more signiﬁcant. Another limitation of our
study is the difﬁculty in distinguishing the malignant
ones from the benign, which needs long-term follow-
up; and our present research has only been undertaken
in a few years, there must be some malignant tumors in
the ‘benign’ group under our present diagnosis.
In conclusion, the results from our study by MLPA
showed that genomic alternation was identiﬁed in
pheochromocytomas and paragangliomas, involving
chromosomes 1p, 3p, 6p, 11q, 12q, 17q, and 19q. Gain
of ERBB-2 oncogene located on chromosome 17q was
an obvious difference between malignancy and benign
tumors. IHC analysis of ERBB-2 further conﬁrmed
that the expression of ERBB-2 in malignant tumors
was much higher than that in the benign ones, whereas
no ERBB-2 protein expression was found in normal
tissues. The association of ERBB-2 gene in breast
cancers and prostate cancer has been widely elucidated
in many studies, and the current study was only a clue
to yet another possible association between ERBB-2
and pheochromocytomas, and paragangliomas, and
further investigation might clarify this connection.
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